Abstract | PURPOSE: METHODS: RESULTS:
Abiraterone treatment resulted in significant reduction in the intracellular levels of 17-OH progesterone and DHT in both LnCap and PC3 cells. FGF-2 and HGF were found to decrease the intracellular levels of 17-OH progesterone in both cell lines, whereas HGF alone was found to increase the intracellular levels of DHT only in PC3 cells. However, the simultaneous exposure of cells to abiraterone and FGF-2 or HGF was found to result in an increase in the intracellular levels of DHT, while it did not result in changes in the intracellular levels of 17-OH progesterone. CONCLUSION: These findings suggest that FGF-2 and HGF may act as an escape mechanism, aiding the development of resistance to abiraterone by restoring intra-tumoral androgen synthesis that may contribute to disease progression.
|
Authors | Chrysoula Vasileiou, Christina Befani, Konstantinos Dimas, Panagiotis Liakos, Christos Papandreou |
Journal | Journal of B.U.ON. : official journal of the Balkan Union of Oncology
(J BUON)
2020 Mar-Apr
Vol. 25
Issue 2
Pg. 1141-1147
ISSN: 2241-6293 [Electronic] Cyprus |
PMID | 32521918
(Publication Type: Journal Article)
|
Chemical References |
- Androstenes
- HGF protein, human
- Dihydrotestosterone
- Fibroblast Growth Factor 2
- Hepatocyte Growth Factor
- abiraterone
|
Topics |
- Androstenes
(pharmacology)
- Cell Line, Tumor
- Dihydrotestosterone
(metabolism)
- Drug Resistance, Neoplasm
- Fibroblast Growth Factor 2
(metabolism)
- Hepatocyte Growth Factor
(metabolism)
- Humans
- Male
- Prostatic Neoplasms
(drug therapy, pathology)
|